PCV salvage chemotherapy for recurrent primary CNS lymphoma.
Herrlinger
U
U
Departments of Neurology, University of Tübingen, Tübingen, Germany. ulrich.herrlinger@uni-tuebingen.de
Brugger
W
W
Bamberg
M
M
Küker
W
W
Dichgans
J
J
Weller
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008130:Lomustine / Q000009:adverse effects / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine